Showing results (221-230 of 286) with videos related to
Sort By:
Pageof 29
European Journal of Cancer (Oxford, England : 1990)|August 11, 2019
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trialAlexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal AntibodyNeil H Segal, Theodore F Logan, F Stephen Hodi, et al.European Journal of Cancer (Oxford, England : 1990)|September 27, 2021
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006Omid Hamid, Caroline Robert, Adil Daud, et al.The New England Journal of Medicine|April 21, 2015
Pembrolizumab versus Ipilimumab in Advanced MelanomaCaroline Robert, Jacob Schachter, Georgina V Long, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2017
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic MelanomaCaroline Robert, Antoni Ribas, Omid Hamid, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder CancerChristophe Massard, Michael S Gordon, Sunil Sharma, et al.Neuro-Oncology Advances|May 10, 2024
POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with <i>BRAF</i> V600-mutant melanoma with brain metastasisAlexander M Menzies, Georgina V Long, Amiee Kohn, et al.Journal of Translational Medicine|July 24, 2019
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)Paolo A Ascierto, Sanjiv S Agarwala, Gerardo Botti, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2016
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With PembrolizumabF Stephen Hodi, Wen-Jen Hwu, Richard Kefford, et al.The Lancet. Oncology|February 7, 2017
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trialCorneel Coens, Stefan Suciu, Vanna Chiarion-Sileni, et al.Pageof 29